OneMedNet Corporation (ONMDW) स्टॉक विश्लेषण

कंपनी का अवलोकन

OneMedNet Corporation operates as a specialized healthcare software provider focused on delivering digital medical image management, exchange, and sharing solutions across the Americas, Europe, and the Middle East regions. The company's core product offering, iRWD, is designed to supply regulatory-grade imaging and clinical data specifically for the pharmaceutical and medical device manufacturing sectors. Although the available data lists the sector and industry classifications as N/A, the enterprise functions within the broader healthcare technology infrastructure necessary for global clinical trials and regulatory compliance. The company's current market capitalization is not disclosed in the provided financial metrics, and its annual revenue stands at $1.36 million over the trailing twelve months. These figures suggest a small-cap entity with a niche market focus, where the lack of a disclosed employee count and market cap implies a structure typical of early-stage or micro-cap biotech software firms. The limited scale indicated by the revenue of $1.36 million suggests the company is in a growth phase where top-line expansion takes precedence over profitability or establishing a large-scale operational footprint.

वित्तीय स्वास्थ्य

The company reported a revenue of $1.36 million for the trailing twelve months, yet it generated a net income of -$2,801,000, revealing a significant negative gap between top-line sales and bottom-line earnings. This substantial disparity indicates a cost structure where operating expenses and losses heavily outweigh the revenue generated from image management services. The enterprise also recorded an EBITDA of -$9,602,000, further highlighting the intense burn rate associated with its software development and regulatory compliance efforts. Free cash flow stands at -$7,840,750, which signifies a lack of financial flexibility and an ongoing reliance on external capital to fund operations and growth initiatives. All three margin metrics present negative figures: the gross margin is -37.0%, the operating margin is -345.9%, and the profit margin is -206.1%. These negative percentages indicate that for every dollar of revenue, the company incurs significant losses before interest and taxes, as well as after all operating expenses and interest are deducted. The balance sheet shows cash reserves of $585,000 against total debt of $974,000, resulting in a net cash position that is negative. The debt-to-equity ratio is not provided in the available data, but the negative cash position suggests the company is leveraged relative to its liquid assets. The current ratio is 0.43, which indicates that the company's current assets are less than half of its current liabilities, pointing to potential short-term liquidity constraints. Return on equity and return on assets are not available for calculation, but the reported return on assets is -205.6%, revealing that management is currently generating substantial losses on the assets employed in the business.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is N/A due to the company's negative earnings, while the forward P/E is also N/A, implying that traditional earnings-based valuation multiples are not applicable at this stage. The price-to-book ratio is -1.21, a negative figure that indicates the market values the company's equity below its book value, often seen in distressed or pre-revenue technology firms. The price-to-sales ratio is N/A, and the EV/EBITDA metric is also N/A, suggesting that investors must rely on alternative metrics like revenue growth or asset backing to value the stock. The 52-week high and 52-week low are both recorded at $0.07, indicating that the stock price has been stagnant or range-bound within a very narrow band. Since the current trading price is not explicitly provided in the facts, the price sits at the lower bound of its 52-week range, reflecting limited price appreciation over the past year. The beta value is 1.17, which means the stock exhibits higher volatility than the broader market and tends to amplify market movements by approximately 17%. This elevated beta suggests that the stock is more sensitive to market fluctuations, a characteristic common in small-cap biotech and software sectors.

Growth & Income

Revenue growth over the year-over-year period is an extraordinary 3326.9%, demonstrating a massive expansion in top-line sales likely driven by new contract acquisitions or scaling of the iRWD platform. Earnings growth is N/A due to the company's negative net income, which prevents a meaningful comparison between revenue expansion and profitability acceleration. The company does not pay dividends, as the dividend yield and payout ratio are listed as N/A, indicating that it reinvests all available resources back into its business operations rather than distributing cash to shareholders. This reinvestment strategy is typical for high-growth software companies that prioritize scaling their technological solutions and regulatory compliance capabilities over providing immediate income. The overall growth profile is characterized by exceptional revenue expansion that has not yet translated into profitability, while the income profile remains non-existent due to the negative net income and lack of dividend payments.